Nkarta, Inc. (NKTX) Stock Price & Analysis
Nkarta, Inc. (NKTX) rose 4.66% to USD 2.92 as of September 8, 2026 at 05:02 UTC, according to Nexqual real-time market data.
NKTX last closed at USD 2.92; the session ranged USD 2.76–2.93 on volume of 447,412 shares. Market capitalization is —, with a 52-week range of USD 1.7–3.72 (NMS). Source: Nexqual, September 8, 2026 at 05:02 UTC.
Key Statistics (as of September 8, 2026 at 05:02 UTC)
| Price | USD 2.92 |
|---|---|
| Change | ▲ 4.66% (up) |
| Previous Close | USD 2.92 |
| Open | USD 2.92 |
| Day Range | USD 2.76 – 2.93 |
| 52-Week Range | USD 1.7 – 3.72 |
| Volume | 447,412 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (NKTX)
Nexqual's technical model rates NKTX "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 05:02 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.71 (neutral) |
| vs SMA50 | Above (USD 2.61) |
| MACD | 0.09 (positive) |
From Nkarta, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary NK cell engineering platform is based on a modular and generalizable approach that we believe enables us to generate next generation and new product candidates in a rapid and cost-efficient manner.
- Below are the five core technologies that comprise our proprietary platform.
- We have developed proprietary technologies designed to generate an abundant supply of NK cells, increase NK cell recognition of target antigens, and enhance NK cell fitness to support scalable, off the shelf administration.
- Continue to progress our proprietary manufacturing capabilities to enable speed, control, flexibility, scalability, and cost efficiency.
Partnerships
- Composition-of-matter claims relating to our NKSTIM cells are estimated to have expired in Q4 2024, subject to any patent term adjustments or extensions. 15   In August 2016, we entered into a license agreement with the Licensors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc. | USD 2.01 | ▼ 3.37% |
| PLRX | Pliant Therapeutics, Inc. | USD 1.16 | ▲ 0% |
| BDTX | Black Diamond Therapeutics, Inc | USD 2.12 | ▼ 0.93% |
| CCCC | C4 Therapeutics, Inc. | USD 3.76 | ▼ 0.79% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 14.97 | ▲ 0.2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:02 UTC. This page is informational and not investment advice.